Altru Telehealth: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Altru Telehealth’s website, https://altrutelehealth.com, FDA Establishment Identifier (FEI) 3044020130, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

1. 1

   “1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Compounded semaglutide combines the FDA approved active ingredient semaglutide with a body safe vitamin such as B12.” “Compounded semaglutide & tirzepatide offers the same results but at a fraction of the cost of brand names such as Ozempic, Mounjaro & Wegovy.” “Semaglutide & Tirzepatide is the active ingredient used in FDA-Approved weekly injection Wegovy® and Mounjaro….“ Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

2. 2

   “2. Your website claims ”[a]n FDA approved, regulated & sterile compounding pharmacy mixes the formula based on the medical providers [sic] prescription” and “[o]ur compounding pharmacies are all FDA approved....” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed” designation for pharmacies or outsourcing facilities. Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

altrutelehealth.com redirected to www.altrutelehealth.com and returned a live site on 2026-08-09 titled "Online Urgent Care in 2 Hours | Altru Telehealth", selling urgent-care visits from $36.99. The compounded weight-loss line the letter concerns was not visible: the fetched homepage contained no occurrence of "semaglutide", "tirzepatide" or "GLP-1", and /weight-loss returned HTTP 404. The company is plainly operating; what is not visible is the product the letter is about.

Most of these letters argue about a sentence describing a drug. This one quotes a sentence describing a bargain — the same results at a fraction of the cost — and that is a different kind of claim to weigh, because it is the one a price comparison actually rests on. "Same active ingredient" is a chemistry statement you can check. "Same results" is a claim about outcomes in people, and compounded versions have not been through the trials that would establish it, which is precisely FDA's point. The savings may still be real; what the letter disputes is the promise that nothing is given up in exchange for them. The second finding matters for a related reason. Told that a pharmacy is "FDA approved, regulated & sterile", a reader reasonably stops asking who mixes the drug. FDA's response is that there is no such approval to have. Neither finding says the medication is unsafe, and neither says the price is wrong — they say the two reassurances offered alongside that price were not the agency's to give.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Altru Telehealth failed to respond.